Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
The commercialisation of Novo Nordisk’s obesity treatment Wegovy and other similar therapeutics has led to an increase in investment from contract manufacturers into fill-finish capabilities involving injection pens to administer the drug.
In a series of interviews, company executives, analysts, and investors have stated that pharmaceutical service providers are hustling to include fill-finish processes into their portfolios. Wegovy and other obesity treatments are administered with injection pens, and the filling of these syringes require specialist work by pharmaceutical manufacturers. Wegovy alone soared in sales since launching in the United States in June 2021.
Tejas Savant, Senior Healthcare Equity Analyst at Morgan Stanely, commented that “Every manufacturer that has sterile fill-finish capacity wants to add more, to get ahead, because it’s not just about Wegovy anymore – you also have Lilly’s Mounjaro coming, and others.” Mounjaro, developed by Eli Lilly, is expected to be approved as a weight-loss treatment in the United States by the end of 2023. In an interview with Reuters, WuXi Biologics CEO Chris Chen revealed that talks with clients have included discussion about utilising pre-filled syringe capacities at a German factory the company bought in 2020.
Such weight-loss injections are classed under a group of drugs known as GLP-1 agonists. Within a decade, experts are expecting such drugs to be worth almost USD $100 billion. This includes the potential for oral treatments, which are now under development by the likes of Pfizer and other pharmaceutical giants. Contract manufacturers are thus in a unique position to get ahead of the curve, providing the manufacturing capabilities for future dosage forms of these weight-loss treatments.
Source: Weight-loss drugs fuel boom for firms that fill syringes [Accessed 9 October 2023] https://www.reuters.com/business/healthcare-pharmaceuticals/weight-loss-drugs-fuel-boom-firms-that-fill-syringes-2023-10-09/
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...